EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study

Maxim Grymonprez iD, Mirko Petrovic, Tine L De Backer, M Arfan Ikram, Stephane Steurbaut, Lies Lahousse

Age and Ageing · 2023

DOI: 10.1093/ageing/afad038 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Age and Ageing, 2023. Verfasst von Maxim Grymonprez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium. Hauptthemen laut MEDLINE: Atrial Fibrillation, Dementia, Stroke. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Foundation Flanders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atrial fibrillation (AF) is associated with cognitive decline, with anticoagulated subjects potentially having a reduced risk compared with non-anticoagulated subjects. However, whether non-vitamin K antagonist oral anticoagulants (NOACs) may reduce the risk of dementia compared with vitamin K antagonists (VKAs) is unclear yet. Therefore, the risk of dementia was compared between AF subjects on NOACs versus VKAs.

Methods

AF subjects initiating anticoagulation between 2013 and 2019 were identified in Belgian nationwide data. Inverse probability of treatment weighted Cox regression was used to investigate cognitive outcomes.

Results

Among 237,012 AF subjects (310,850 person-years (PYs)), NOAC use was associated with a significantly lower risk of dementia (adjusted hazard ratio (aHR) 0.91, 95% confidence interval (CI) (0.85–0.98)) compared with VKAs. A trend towards a lower risk of vascular dementia (aHR 0.89, 95% CI (0.76–1.04)) and significantly lower risk of other/unspecified dementia (aHR 0.91, 95% CI (0.84–0.99)) were observed with NOACs compared with VKAs, whereas the risk of Alzheimer’s disease was similar (aHR 0.99, 95% CI (0.88–1.11)). Apixaban (aHR 0.91, 95% CI (0.83–0.99)) and edoxaban (aHR 0.79, 95% CI (0.63–0.99)) were associated with significantly lower risks of dementia compared with VKAs, while risks were not significantly different with dabigatran (aHR 1.02, 95% CI (0.93–1.12)) and rivaroxaban (aHR 0.97, 95% CI (0.90–1.05)). Comparable risks of dementia were observed between individual NOACs, except for significantly lower risks of dementia (aHR 0.93, 95% CI (0.87–0.98)) and other/unspecified dementia (aHR 0.90 (0.84–0.97)) with apixaban compared with rivaroxaban.

Conclusion

NOACs were associated with a significantly lower risk of dementia compared with VKAs, likely driven by apixaban and edoxaban use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDementiaStrokeHumansAnticoagulantsRivaroxabanCohort StudiesAdministration, OralBelgiumDabigatranPyridinesThiazoles

Stichwörter der Autor:innen

Alzheimer’s diseaseatrial fibrillationdementianon-vitamin K antagonist oral anticoagulants (NOAC)vitamin K antagonists (VKA)

Substanzen

AnticoagulantsRivaroxabanDabigatranedoxabanPyridinesThiazoles

Autor:innen und Institutionen

  • Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.
  • Department of Geriatrics, Ghent University Hospital, 9000 Ghent, Belgium.
  • Department of Cardiology, Ghent University Hospital, 9000 Ghent, Belgium.
  • Department of Epidemiology, Erasmus Medical Center, 3000 Rotterdam, The Netherlands.
  • Centre for Pharmaceutical Research, Research group of Clinical Pharmacology and Clinical Pharmacy, Vrije Universiteit Brussel, 1090 Jette, Belgium.
  • Department of Hospital Pharmacy, UZ Brussel, 1090 Jette, Belgium.

ORCID-Profile: Maxim Grymonprez

Förderung

  • Research Foundation Flanders

Zitieren

APA

Grymonprez, M., Petrovic, M., De Backer, T. L., Ikram, M. A., Steurbaut, S., & Lahousse, L. (2023). Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study. Age and Ageing. https://doi.org/10.1093/ageing/afad038

Vancouver

Grymonprez M, Petrovic M, De Backer TL, Ikram MA, Steurbaut S, Lahousse L. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study. Age and Ageing. 2023. doi:10.1093/ageing/afad038

BibTeX
@article{Grymonprez2023,
  author = {Grymonprez, Maxim and Petrovic, Mirko and De Backer, Tine L and Ikram, M Arfan and Steurbaut, Stephane and Lahousse, Lies},
  title = {Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study},
  journal = {Age and Ageing},
  year = {2023},
  doi = {10.1093/ageing/afad038}
}
Kostenlos starten →